Novo TTF was FDA approved in April 2011 under orphan disese designation for recurrent glioblastoma.. Several prominent neuronoologists were trained in tis use and it now available in these individuals' centers. TTF therapy has been shown in vitro and in vivo to effectively inhibit tumor growth by inducing cell death. TTF takes advantage of the electrical characteristics, geometrical shape and replication rate of dividing cancer cells – all of which makes them susceptible to the effects of alternating electric fields. TTF therapy is delivered using non-invasive, insulated transducer arrays that are placed directly on the skin in the region of the tumor. TTF therapy does not deliver any electric current to the tissue; it does not stimulate nerves or muscles or heat the tissue. It creates an artificial, alternating electric field within the tumor which disrupts cancer cell division and can cause complete destruction of the dividing cancer cells.
The supporting trial subgroup analysis was presented as abstract Number: NO-55 entitled, Subgroup and quality of life analyses of the phase III clinical trial of NovoTTF-100A versus best standard chemotherapy for recurrent glioblastoma at Society of Neuro-oncology on September 19, 2010.
In a randomized Phase III clinical trial, the NovoTTF-100A device has at least equivalent efficacy, and with fewer treatment-related side effects, to the salvage cytotoxic chemotherapies that have established efficacy against recurrent glioblastoma.
Stupp R, Kanner A, Engelhard H et al. A prospective, randomized, open-label,
Phase III clinical of NovoTTF-100A versus best standard of care chemotherapy in
patients with recurrent glioblastoma. J. Clin. Oncol. 28(18), LBA2007 (2011).
Comments